Aurobindo Pharma’s Q3 FY25 Results: Profit Declines Despite Revenue Growth
Aurobindo Pharma reported its Q3 FY25 results, revealing a 10% year-on-year (YoY) decline in consolidated net profit after tax (PAT) to ₹845.56 crore, compared to ₹939.97 crore for the same period last year. The net profit came on an 8.5% increase in the revenue from operations to ₹7,978.5 crore (₹7,351.7 crore). Total expenditure increased to … Read more